Published in ACS Infect Dis on January 22, 2017
Clinical development success rates for investigational drugs. Nat Biotechnol (2014) 5.32
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis (2010) 2.08
Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci (2010) 2.06
SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis (2011) 1.66
Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother (2011) 1.37
Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. J Med Chem (2012) 1.35
Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection. Structure (2012) 1.18
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity. J Med Chem (2011) 1.05
Identification of potent inhibitors of the Trypanosoma brucei methionyl-tRNA synthetase via high-throughput orthogonal screening. J Biomol Screen (2014) 1.00
Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign. PLoS Negl Trop Dis (2014) 1.00
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. J Med Chem (2013) 0.97
Structures of Trypanosoma brucei methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sickness. PLoS Negl Trop Dis (2014) 0.95
Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for mu opioid and I2-imidazoline receptors: synthesis and pharmacological screening. Bioorg Med Chem (2002) 0.90
Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against Giardia intestinalis Trophozoites. Antimicrob Agents Chemother (2015) 0.87
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays. J Med Chem (2012) 0.85
Synthesis and antitubercular activity evaluation of novel unsymmetrical cyclohexane-1,2-diamine derivatives. Arch Pharm (Weinheim) (2012) 0.82
Ionic liquid crystals derived from amino acids. Chemistry (2013) 0.80
Two sensor kinases contribute to the hypoxic response of Mycobacterium tuberculosis. J Biol Chem (2004) 2.71
Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov (2008) 2.58
Type II secretion: from structure to function. FEMS Microbiol Lett (2006) 2.51
Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol (2006) 2.45
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol (2010) 2.34
Structure of the GspK-GspI-GspJ complex from the enterotoxigenic Escherichia coli type 2 secretion system. Nat Struct Mol Biol (2008) 2.19
The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci U S A (2002) 2.10
The type II secretion system: biogenesis, molecular architecture and mechanism. Nat Rev Microbiol (2012) 1.96
Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody. Structure (2009) 1.89
Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J Med Chem (2009) 1.87
Sites of interaction between aldolase and thrombospondin-related anonymous protein in plasmodium. Mol Biol Cell (2003) 1.83
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem (2005) 1.81
Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem (2009) 1.73
The 1.6-A crystal structure of the class of chaperones represented by Escherichia coli Hsp31 reveals a putative catalytic triad. Proc Natl Acad Sci U S A (2003) 1.72
High resolution crystal structure of a key editosome enzyme from Trypanosoma brucei: RNA editing ligase 1. J Mol Biol (2004) 1.67
Structural basis for the activation of cholera toxin by human ARF6-GTP. Science (2005) 1.66
Structural basis for UTP specificity of RNA editing TUTases from Trypanosoma brucei. EMBO J (2005) 1.61
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol (2003) 1.61
The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem (2005) 1.60
Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem (2007) 1.60
Secretins: dynamic channels for protein transport across membranes. Trends Biochem Sci (2011) 1.58
Crystal structure of the extracellular protein secretion NTPase EpsE of Vibrio cholerae. J Mol Biol (2003) 1.55
The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1. Structure (2002) 1.51
An improved protocol for rapid freezing of protein samples for long-term storage. Acta Crystallogr D Biol Crystallogr (2003) 1.49
Crystal structure of a transition state mimic for Tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide. Chem Biol (2003) 1.47
Structure of the cholera toxin secretion channel in its closed state. Nat Struct Mol Biol (2010) 1.44
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43
Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. J Mol Biol (2002) 1.37
Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother (2011) 1.37
Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res (2005) 1.36
Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1. J Med Chem (2012) 1.35
Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. J Med Chem (2012) 1.35
The X-ray structure of the type II secretion system complex formed by the N-terminal domain of EpsE and the cytoplasmic domain of EpsL of Vibrio cholerae. J Mol Biol (2005) 1.33
The power of vanadate in crystallographic investigations of phosphoryl transfer enzymes. FEBS Lett (2004) 1.32
Aldolase provides an unusual binding site for thrombospondin-related anonymous protein in the invasion machinery of the malaria parasite. Proc Natl Acad Sci U S A (2007) 1.31
GAF domains: two-billion-year-old molecular switches that bind cyclic nucleotides. Mol Interv (2002) 1.29
Heterologous expression of L. major proteins in S. cerevisiae: a test of solubility, purity, and gene recoding. J Struct Funct Genomics (2009) 1.28
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem (2011) 1.28
Structures of Mycobacterium tuberculosis DosR and DosR-DNA complex involved in gene activation during adaptation to hypoxic latency. J Mol Biol (2005) 1.26
Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligands. J Biomol Screen (2009) 1.25
Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol (2008) 1.22
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother (2008) 1.21
Synergistic stimulation of EpsE ATP hydrolysis by EpsL and acidic phospholipids. EMBO J (2006) 1.21
Crystal structures of the response regulator DosR from Mycobacterium tuberculosis suggest a helix rearrangement mechanism for phosphorylation activation. J Mol Biol (2008) 1.20
Structural genomics of pathogenic protozoa: an overview. Methods Mol Biol (2008) 1.20
Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection. Structure (2012) 1.18
The closed MTIP-myosin A-tail complex from the malaria parasite invasion machinery. J Mol Biol (2007) 1.15
The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA. J Mol Biol (2006) 1.14
The structure of the cytoplasmic domain of EpsL, an inner membrane component of the type II secretion system of Vibrio cholerae: an unusual member of the actin-like ATPase superfamily. J Mol Biol (2004) 1.14
Structural and functional studies of EpsC, a crucial component of the type 2 secretion system from Vibrio cholerae. J Mol Biol (2006) 1.13
Structure of the Mycobacterium tuberculosis flavin dependent thymidylate synthase (MtbThyX) at 2.0A resolution. J Mol Biol (2005) 1.13
Structure of the minor pseudopilin EpsH from the Type 2 secretion system of Vibrio cholerae. J Mol Biol (2007) 1.12
Structural and functional studies on the interaction of GspC and GspD in the type II secretion system. PLoS Pathog (2011) 1.12
The role of medical structural genomics in discovering new drugs for infectious diseases. PLoS Comput Biol (2009) 1.11
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem (2010) 1.11
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem (2009) 1.10
Crystal structures of an intrinsically active cholera toxin mutant yield insight into the toxin activation mechanism. Biochemistry (2004) 1.09
Structure of the MTIP-MyoA complex, a key component of the malaria parasite invasion motor. Proc Natl Acad Sci U S A (2006) 1.09
Parasitology. Drugs to combat tropical protozoan parasites. Science (2002) 1.08
A protein-protein interaction map of trypanosome ~20S editosomes. J Biol Chem (2009) 1.08
Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin. J Am Chem Soc (2002) 1.08
Explorations of peptide and oligonucleotide binding sites of tyrosyl-DNA phosphodiesterase using vanadate complexes. J Med Chem (2004) 1.07
The crystal structure of a binary complex of two pseudopilins: EpsI and EpsJ from the type 2 secretion system of Vibrio vulnificus. J Mol Biol (2007) 1.07
Leishmania major activates IL-1 alpha expression in macrophages through a MyD88-dependent pathway. Microbes Infect (2002) 1.07
In vivo cross-linking of EpsG to EpsL suggests a role for EpsL as an ATPase-pseudopilin coupling protein in the Type II secretion system of Vibrio cholerae. Mol Microbiol (2011) 1.07
Calcium is essential for the major pseudopilin in the type 2 secretion system. J Biol Chem (2009) 1.05
Structures of enterococcal glycerol kinase in the absence and presence of glycerol: correlation of conformation to substrate binding and a mechanism of activation by phosphorylation. Biochemistry (2004) 1.05
The crystal structure of the periplasmic domain of the type II secretion system protein EpsM from Vibrio cholerae: the simplest version of the ferredoxin fold. J Mol Biol (2004) 1.04
Use of thermal melt curves to assess the quality of enzyme preparations. Anal Biochem (2009) 1.02
Biogenesis of peroxisomes and glycosomes: trypanosomatid glycosome assembly is a promising new drug target. FEMS Microbiol Rev (2004) 1.02
Crystal structure of an IdeR-DNA complex reveals a conformational change in activated IdeR for base-specific interactions. J Mol Biol (2004) 1.01
Functional studies of the Mycobacterium tuberculosis iron-dependent regulator. J Biol Chem (2004) 1.01
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chem Rev (2014) 1.00
Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J Med Chem (2006) 1.00
Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin. J Am Chem Soc (2002) 1.00
Structure of a Trypanosoma brucei alpha/beta-hydrolase fold protein with unknown function. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.99
Structures of substrate- and inhibitor-bound adenosine deaminase from a human malaria parasite show a dramatic conformational change and shed light on drug selectivity. J Mol Biol (2008) 0.98
Structural insights into the recognition of peroxisomal targeting signal 1 by Trypanosoma brucei peroxin 5. J Mol Biol (2008) 0.97
Crystal structures of trypanosomal histidyl-tRNA synthetase illuminate differences between eukaryotic and prokaryotic homologs. J Mol Biol (2010) 0.97
Crystal structure of a heterodimer of editosome interaction proteins in complex with two copies of a cross-reacting nanobody. Nucleic Acids Res (2011) 0.97
Precursor structure of cephalosporin acylase. Insights into autoproteolytic activation in a new N-terminal hydrolase family. J Biol Chem (2001) 0.96
A new native EcHsp31 structure suggests a key role of structural flexibility for chaperone function. Protein Sci (2004) 0.96
The binding of cholera toxin to the periplasmic vestibule of the type II secretion channel. Channels (Austin) (2011) 0.96
Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis. J Med Chem (2014) 0.96
Structures of a key interaction protein from the Trypanosoma brucei editosome in complex with single domain antibodies. J Struct Biol (2010) 0.95